NASDAQ:EQ Equillium (EQ) Stock Forecast, Price & News $0.63 +0.01 (+1.11%) (As of 02:57 PM ET) Add Compare Share Share Today's Range$0.63▼$0.6450-Day Range$0.49▼$0.7952-Week Range$0.48▼$3.20Volume23,356 shsAverage Volume184,150 shsMarket Capitalization$21.61 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Equillium MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside931.6% Upside$6.50 Price TargetShort InterestBearish3.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.64) to ($0.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 starsMedical Sector929th out of 1,980 stocksPharmaceutical Preparations Industry447th out of 978 stocks 3.5 Analyst's Opinion Consensus RatingEquillium has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Equillium has a forecasted upside of 931.6% from its current price of $0.63.Amount of Analyst CoverageEquillium has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.50% of the float of Equillium has been sold short.Short Interest Ratio / Days to CoverEquillium has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Equillium has recently increased by 14.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEquillium does not currently pay a dividend.Dividend GrowthEquillium does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EQ. Previous Next 1.7 News and Social Media Coverage News SentimentEquillium has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Equillium this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Equillium to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Equillium insiders have not sold or bought any company stock.Percentage Held by Insiders30.00% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.64% of the stock of Equillium is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Equillium are expected to grow in the coming year, from ($0.64) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Equillium is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Equillium is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEquillium has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Equillium (NASDAQ:EQ) StockEquillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA.Read More Receive EQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter. Email Address EQ Stock News HeadlinesJune 1, 2023 | finance.yahoo.comEquillium to Present at the Jefferies Global Healthcare & LD Micro Invitational ConferencesMay 17, 2023 | americanbankingnews.comFY2023 EPS Estimates for Equillium, Inc. (NASDAQ:EQ) Boosted by Cantor FitzgeraldJune 2, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 17, 2023 | americanbankingnews.comHC Wainwright Weighs in on Equillium, Inc.'s Q2 2023 Earnings (NASDAQ:EQ)May 16, 2023 | msn.comHC Wainwright & Co. Reiterates Equillium (EQ) Buy RecommendationMay 15, 2023 | finance.yahoo.comEquillium Announces Poster Presentation at the Annual Meeting of The American Association of ImmunologistsMay 11, 2023 | msn.comEquillium GAAP EPS of -$0.11 beats by $0.07, revenue of $8.9MMay 11, 2023 | finance.yahoo.comEquillium Reports First Quarter 2023 Financial Results and Provides Clinical UpdatesJune 2, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 5, 2023 | americanbankingnews.comEquillium, Inc. (NASDAQ:EQ) Expected to Post Q1 2023 Earnings of $0.05 Per ShareMay 3, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Meaningful Upgrade To Their Equillium, Inc. (NASDAQ:EQ) ForecastsMay 1, 2023 | americanbankingnews.comEquillium (NASDAQ:EQ) PT Lowered to $5.50 at HC WainwrightApril 6, 2023 | americanbankingnews.comReviewing Equillium (NASDAQ:EQ) & Akari Therapeutics (NASDAQ:AKTX)April 4, 2023 | americanbankingnews.comEquillium, Inc. (NASDAQ:EQ) Sees Significant Increase in Short InterestMarch 25, 2023 | americanbankingnews.comStifel Nicolaus Cuts Equillium (NASDAQ:EQ) Price Target to $7.00March 23, 2023 | finance.yahoo.comEquillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development UpdatesMarch 22, 2023 | finance.yahoo.comEquillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease ConferenceMarch 22, 2023 | businesswire.comEquillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease ConferenceFebruary 7, 2023 | finance.yahoo.comEquillium to Present at the SVB Securities Annual Global Healthcare ConferenceJanuary 13, 2023 | finance.yahoo.comEquillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRDecember 16, 2022 | finance.yahoo.comEquillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative ColitisDecember 14, 2022 | finance.yahoo.comAutoimmune Biotech Scores $26M Payment, Up To $139M To Advance Phase 3 ResearchDecember 6, 2022 | finance.yahoo.comEquillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of ItolizumabNovember 15, 2022 | finance.yahoo.comEquillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical UpdatesNovember 14, 2022 | finance.yahoo.comEquillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022November 10, 2022 | finance.yahoo.comEquillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia AreataNovember 3, 2022 | finance.yahoo.comEquillium Announces Presentation at the 6th Annual Dermatology Drug Development SummitSee More Headlines EQ Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EQ Company Calendar Last Earnings3/23/2023Today6/02/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EQ CUSIPN/A CIK1746466 Webequilliumbio.com Phone(858) 240-1200FaxN/AEmployees45Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$5.50 Forecasted Upside/Downside+906.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,430,000.00 Net MarginsN/A Pretax Margin-117.26% Return on Equity-89.33% Return on Assets-44.32% Debt Debt-to-Equity Ratio0.06 Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual Sales$15.76 million Price / Sales1.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book0.76Miscellaneous Outstanding Shares34,410,000Free Float24,090,000Market Cap$22.22 million OptionableNot Optionable Beta1.19 Key ExecutivesBruce D. SteelPresident, Chief Executive Officer & DirectorChristine ZedelmayerChief Operating Officer & Senior Vice PresidentJason A. KeyesChief Financial OfficerStephen ConnellyDirector & Chief Scientific OfficerJoel M. RothmanChief Development OfficerKey CompetitorsVaccinexNASDAQ:VCNXLiminal BioSciencesNASDAQ:LMNLForte BiosciencesNASDAQ:FBRXVYNE TherapeuticsNASDAQ:VYNECocrystal PharmaNASDAQ:COCPView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 1,619,000 shares on 5/18/2023Ownership: 4.705%Victory Capital Management Inc.Sold 2,852,884 shares on 5/2/2023Ownership: 1.005%Jason A KeyesSold 7,000 sharesTotal: $19,810.00 ($2.83/share)Jason A KeyesSold 5,000 sharesTotal: $12,600.00 ($2.52/share)View All Insider TransactionsView All Institutional Transactions EQ Stock - Frequently Asked Questions Should I buy or sell Equillium stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EQ shares. View EQ analyst ratings or view top-rated stocks. What is Equillium's stock price forecast for 2023? 3 brokerages have issued 12-month price objectives for Equillium's shares. Their EQ share price forecasts range from $5.50 to $7.00. On average, they anticipate the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 906.5% from the stock's current price. View analysts price targets for EQ or view top-rated stocks among Wall Street analysts. How have EQ shares performed in 2023? Equillium's stock was trading at $1.06 at the start of the year. Since then, EQ stock has decreased by 39.1% and is now trading at $0.6458. View the best growth stocks for 2023 here. Are investors shorting Equillium? Equillium saw a increase in short interest in May. As of May 15th, there was short interest totaling 724,100 shares, an increase of 14.6% from the April 30th total of 632,000 shares. Based on an average daily volume of 160,800 shares, the short-interest ratio is currently 4.5 days. Currently, 3.5% of the shares of the stock are short sold. View Equillium's Short Interest. When is Equillium's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our EQ earnings forecast. How were Equillium's earnings last quarter? Equillium, Inc. (NASDAQ:EQ) posted its earnings results on Thursday, March, 23rd. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.41. The business had revenue of $15.76 million for the quarter, compared to analyst estimates of $26 million. What is Geoffrey A. Rotstein's approval rating as Equillium's CEO? 10 employees have rated Equillium Chief Executive Officer Geoffrey A. Rotstein on Glassdoor.com. Geoffrey A. Rotstein has an approval rating of 50% among the company's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 76.0% of employees surveyed would recommend working at Equillium to a friend. When did Equillium IPO? (EQ) raised $70 million in an initial public offering (IPO) on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO. What is Equillium's stock symbol? Equillium trades on the NASDAQ under the ticker symbol "EQ." Who are Equillium's major shareholders? Equillium's stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (4.71%) and Victory Capital Management Inc. (1.01%). Insiders that own company stock include Jason A Keyes, Jason A Keyes and Stephen Connelly. View institutional ownership trends. How do I buy shares of Equillium? Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Equillium's stock price today? One share of EQ stock can currently be purchased for approximately $0.65. How much money does Equillium make? Equillium (NASDAQ:EQ) has a market capitalization of $22.22 million and generates $15.76 million in revenue each year. The company earns $-62,430,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. How can I contact Equillium? Equillium's mailing address is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. The official website for the company is equilliumbio.com. The company can be reached via phone at (858) 240-1200 or via email at ir@equilliumbio.com. This page (NASDAQ:EQ) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.